Oncolytics Biotech Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $56.0M
- Price
- $0.4394
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.09%
- Volume
- 517.0K
About
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Quick stats
Shares outstanding127.5M
Computed float125.1M
Float / shares98.1%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001129928
AI Summary
AI-generated1/31
standardbullishclinical trial
Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers
Oncolytics Biotech presented new translational data at SITC 2026 showing pelareorep, combined with a checkpoint inhibitor, expands HPV-16-specific T cells and tumor-infiltrating lymphocytes in second-line or later anal cancer patients.
Efficacy signals included more than double the objective response rate and 50% longer median duration of response versus the current approved therapy, with two complete and two partial responses among TIL-expanding patients.
Management framed HPV-associated cancers as a $3-5 billion business development opportunity and is actively pursuing strategic partnerships around the data.
Red flags
- early-phase data (Phase 1/2, small patient numbers)
- company explicitly dependent on securing partnerships to advance development